GOT2 and neoplasm: However, clinical translation faces two major challenges (1): Target specificity—current inhibitors (e.g., amino acid analogs) struggle to distinguish between GOT1 and GOT2 isoenzymes; (2) Metabolic compensation risk—tumor cells may activate alternative pathways, such as pyruvate carboxylase, to compensate for GOT2 inhibition, leading to failure of single-target therapies (12, 62).